A patient who underwent transcatheter aortic valve replacement (TAVR) on [date] and is taking apixaban (Eliquis) and clopidogrel (Plavix) now requires cholecystectomy; does he need cardiac clearance and how long should the anticoagulant and antiplatelet therapy be held before surgery?

Cardiac Clearance and Anticoagulation Management for Post-TAVR Patient Requiring Cholecystectomy

For a post-TAVR patient on dual antithrombotic therapy requiring cholecystectomy, formal cardiac clearance is generally not required if the patient is clinically stable, but you should hold Plavix (clopidogrel) for 5-7 days and Eliquis (apixaban) for 2-3 days before surgery, while continuing to assess the patient's cardiac risk factors and ensuring adequate time has passed since the TAVR procedure.

Cardiac Clearance Considerations

Formal preoperative cardiac clearance is typically not necessary for a stable post-TAVR patient undergoing cholecystectomy, but several key factors require assessment:

• Time since TAVR: The date of the TAVR procedure is critical. While not explicitly addressed in guidelines for TAVR specifically, extrapolating from PCI data suggests that if possible, elective surgery should ideally be delayed at least 3 months post-TAVR to allow for valve endothelialization 1.

• Clinical stability: Evaluate for new or worsening symptoms (chest pain, dyspnea, syncope, heart failure) that would warrant cardiology consultation before proceeding.

• Surgical urgency: Cholecystectomy for acute cholecystitis may not allow for optimal timing, requiring a risk-benefit discussion with the surgical team.

A practical approach: Contact the patient's cardiologist to inform them of the planned surgery and confirm clinical stability, but formal "clearance" with extensive testing is unnecessary unless the patient has new cardiac symptoms.

Anticoagulation Management Strategy

Plavix (Clopidogrel) Management

Hold clopidogrel for 5-7 days before cholecystectomy 2, 3, 1. This recommendation is consistent across multiple high-quality guidelines:

• The 2018 Canadian Cardiovascular Society guidelines specifically recommend withholding clopidogrel for 5-7 days preoperatively for noncardiac surgery 1
• The 2022 CHEST guidelines suggest stopping clopidogrel 5-7 days before surgery 4
• Cholecystectomy is considered an intermediate-to-high bleeding risk procedure, making the 5-7 day window appropriate

Important caveat: One small study suggested laparoscopic cholecystectomy could be performed safely without stopping clopidogrel 5, but this contradicts guideline recommendations and should not be standard practice given the established bleeding risk.

Eliquis (Apixaban) Management

Hold apixaban for 2-3 days before cholecystectomy 6, 7. The specific timing depends on bleeding risk assessment:

• For procedures with intermediate or high risk of major bleeding (which includes cholecystectomy): stop apixaban 2-3 days before surgery 6
• The FDA label for Eliquis states it should be discontinued at least 48 hours prior to elective surgery with moderate or high risk of bleeding 7
• Given apixaban's half-life of approximately 12 hours, 48-72 hours (2-3 days) allows for adequate drug clearance

Renal function consideration: If the patient has impaired renal function (though not specified in your case), consider extending the interruption period, as apixaban clearance is partially renal-dependent.

Critical Timing Algorithm

Pre-operative medication holding schedule:

1. Day -7 to -5: Stop clopidogrel (Plavix)
2. Day -3 to -2: Stop apixaban (Eliquis)
3. Day 0: Proceed with cholecystectomy

This staggered approach ensures both medications are adequately cleared while minimizing the duration off anticoagulation.

Bridging Therapy Considerations

Bridging anticoagulation is NOT recommended for this scenario 7. The FDA label for Eliquis explicitly states: "Bridging anticoagulation during the 24 to 48 hours after stopping ELIQUIS and prior to the intervention is not generally required" 7.

Rationale:

• The patient is not at extremely high thrombotic risk (unlike mechanical valves or recent stroke)
• Bridging increases bleeding risk without proven benefit in this population
• The short interruption period (2-3 days for apixaban) minimizes thrombotic risk

Post-operative Resumption

Resume both medications as soon as adequate hemostasis is established 6, 1:

• For low bleeding risk procedures: Resume within 24-48 hours post-operatively
• For intermediate/high bleeding risk procedures (cholecystectomy): Resume within 48-72 hours post-operatively 6
• Coordinate with the surgeon to confirm hemostasis before restarting

Practical approach: Resume apixaban first (within 48-72 hours), then resume clopidogrel once the surgeon confirms stable hemostasis, typically by post-operative day 2-3.

Special Considerations and Pitfalls

Common Pitfalls to Avoid:

1. Don't stop both medications simultaneously - the staggered approach minimizes total time off antithrombotic therapy
2. Don't use bridging therapy - this increases bleeding risk without benefit 7
3. Don't delay resumption unnecessarily - prolonged interruption increases thrombotic risk, especially valve thrombosis risk post-TAVR
4. Don't forget to assess the indication for dual therapy - confirm why the patient is on both agents (was there recent PCI in addition to TAVR? Is there atrial fibrillation?)

Why This Patient is on Both Medications:

Post-TAVR patients are typically on antiplatelet therapy (aspirin ± clopidogrel) rather than anticoagulation unless they have another indication. The presence of both Eliquis and Plavix suggests:

• Atrial fibrillation (indication for Eliquis) PLUS
• Recent TAVR or PCI (indication for Plavix)

This "triple therapy" scenario (though you mention only two drugs, aspirin may also be prescribed) carries higher bleeding risk, making careful perioperative management essential.

Surgical Risk Assessment:

Laparoscopic cholecystectomy is generally considered intermediate bleeding risk. Open cholecystectomy or surgery for complicated cholecystitis may be high bleeding risk. Confirm the planned surgical approach with the surgeon, as this may influence the exact timing of medication resumption.

Documentation:

Clearly document in the medical record:

• Date of last dose of each medication
• Plan for resumption post-operatively
• Communication with cardiology and surgery teams
• Assessment that bridging is not indicated

This ensures all team members are aligned and reduces the risk of premature resumption or unnecessary bridging.